MedDataX Logo

Serotonin, Serotonin Genetics(TPH2) and Emotion and Interference Processing

NCT ID: NCT03549182

Last Updated: 2020-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-01

Study Completion Date

2021-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to explore whether acute tryptophan depletion can affect the emotion and interference processing whether this effect is moderated by the TPH2 genotype

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Based on previous studies suggesting that serotonin, a neurotransmitter, is associated with social \& emotional behavior, including emotional reactivity and emotion regulation, the present study aims to explore effects of acute tryptophan depletion (ATD) on emotion processing and emotional interference processing within a randomized double-blind, with-subject, placebo-controlled pharmaco-fMRI experiment. To further examine the potential moderating effects of the genetic makeup of the serotonin system the present study will include a pharmacogenetics imaging approach. Given that TPH2 is the key regulator of the serotonergic signaling pathway, we therefore assessed whether such the effects of tryptophan depletion vary according to the TPH2 genotype. To this end, healthy male TPH2-GG or TPH2-TT carriers will be recruited and will receive ATD (100g) and placebo (102.3g) in a within subject design. To control for potential effects of pre-medication personality traits as well as effects of medicines on mood, subjects will be administered pre-treatment assessing relevant personality traits and post-treatment assessments of mood.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

acute tryptophan depletion tryptophan hydroxylase 2 gene emotion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

male TPH2-GG carriers with ATD then placebo group

male TPH2-GG carriers will first receive ATD, then will receive placebo at least 5 weeks later.

Group Type EXPERIMENTAL

ATD treatment

Intervention Type DRUG

oral administration of ATD (100g)(Acute Tryptophan Depletion)

placebo treatment

Intervention Type DRUG

oral administration of placebo (102.3g)

male TPH2-GG carriers with placebo then ATD group

male TPH2-GG carriers will first receive placebo, then will receive ATD at least 5 weeks later.

Group Type EXPERIMENTAL

ATD treatment

Intervention Type DRUG

oral administration of ATD (100g)(Acute Tryptophan Depletion)

placebo treatment

Intervention Type DRUG

oral administration of placebo (102.3g)

male TPH2-TTcarriers with ATD then placebo group

male TPH2-TT carriers will first receive ATD, then will receive placebo at least 5 weeks later.

Group Type EXPERIMENTAL

ATD treatment

Intervention Type DRUG

oral administration of ATD (100g)(Acute Tryptophan Depletion)

placebo treatment

Intervention Type DRUG

oral administration of placebo (102.3g)

male TPH2-TTcarriers with placebo then ATD group

male TPH2-TT carriers will first receive placebo,then will receive ATD at least 5 weeks later.

Group Type EXPERIMENTAL

ATD treatment

Intervention Type DRUG

oral administration of ATD (100g)(Acute Tryptophan Depletion)

placebo treatment

Intervention Type DRUG

oral administration of placebo (102.3g)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ATD treatment

oral administration of ATD (100g)(Acute Tryptophan Depletion)

Intervention Type DRUG

placebo treatment

oral administration of placebo (102.3g)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy subjects without past or current psychiatric or neurological disorders
* Right-handedness

Exclusion Criteria

* History of head injury;
* Medical or psychiatric illness.
* High blood pressure, general cardio-vascular alterations
* History of drug or alcohol abuse or addiction.
* Allergy against medications or general strong allergies
* Sleep disorders.
* Visual or motor impairments
Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Electronic Science and Technology of China

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Benjamin Becker

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

School of Life Science and Technology

Chengdu, Sichuan, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Benjamin Becker, Dr.

Role: CONTACT

Phone: 86-28-61830988

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Weihua Zhao

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UESTC-neuSCAN-51

Identifier Type: -

Identifier Source: org_study_id